PMU53 THE INCENTIVE FINANCIAL FRAMEWORK REGARDING FRENCH HOSPITAL PRESCRIPTION OF BIOSIMILAR MEDICINES WHEN DELIVERED IN RETAIL PHARMACY: IMPACT ANALYSIS OF ARTICLE 51 EXPERIMENTATION FOR 2018

Abstract

In 2018, 40 million euros of savings were expected in France thanks to the interchangeability between reference biological medicinal products and biosimilars. In the measures proposed by the French State, the incentive financial framework regarding hospital prescription of biosimilar medicines when delivered in retail pharmacy in the context of the Article 51 experiment participate in these savings. The objective of this study is to evaluate, in France and for the year 2018, the financial impact of this experimental framework. To carry out this work, we first selected, with the help of the legal texts, the medicines and establishments participating in this experimentation. The data used for this exercise comes from the IQVIA Lifelink Treatment Dynamics® database and allowed us to perform the calculations presented in these texts. The results show a nonsignificant impact on the penetration rate of biosimilar drugs and show that there is a no significant savings for the community thanks to the experimental framework in 2018. The objective of obtaining a faster increase of at least 15 points of the biosimilar prescription rate in the establishment participating in the experiment, compared to non-participating establishment is not met. The objective of the general incentive scheme, which is to achieve a strong increase in the rate of use of biosimilar medicines (in 2018) compared to the initial rate (2017), is rather achieved. For all French establishment, penetration rates increased significantly compared to 2017 for both drug groups: + 8.5 points for the Anti Tumor Necrosis Factor group and + 7.3 points for the Insulin group. The entry of the Adalimumab group into the system will play a decisive role in the future savings generated by these incentives as early as 2019.